Crossmark

Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects

Crossref DOI link: https://doi.org/10.1007/s00228-019-02808-9

Published Online: 2019-12-13

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Boof, Marie-Laure https://orcid.org/0000-0002-6734-5674
Halabi, Atef

Ufer, Mike

Dingemanse, Jasper
License Information

Text and Data Mining valid from 2019-12-13

Version of Record valid from 2019-12-13
More Information

Article History

Received: 23 September 2019

Accepted: 27 November 2019

First Online: 13 December 2019

Compliance with ethical standards

: Written informed consent was obtained from all of the subjects. The study was approved by the German health authority (BfArM) and by the Ethics committee (Ethikkommission II, Bad Segeberg, Germany) before its start.

: Marie-Laure Boof, Mike Ufer, and Jasper Dingemanse are employees of Idorsia Pharmaceuticals Ltd. Atef Halabi is employed by Clinical Research Services Kiel GmbH.

Document is current

Any future updates will be listed below